Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05640726
PHASE2

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Sponsor: Fujian Cancer Hospital

View on ClinicalTrials.gov

Summary

To explore the efficacy and safety of radiotherapy followed by PD-1+ standard chemotherapy in the first-line treatment of initial unresectable rectal cancer liver metastases

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2023-05-01

Completion Date

2026-05-01

Last Updated

2022-12-07

Healthy Volunteers

No

Conditions

Interventions

DRUG

PD-1

Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks

RADIATION

SCRT

Radiotherapy dose: 5×5 Gy

DRUG

Bevacizumab

Participants will receive bevacizumab,5mg/kg,intravenously over 60 - 90 minutes, day 1 of every 2 weeks

DRUG

Oxaliplatin

Participants will receive Oxaliplatin,85mg/m2,day1

DRUG

Calcium folinate

Participants will receive calcium folinate ,400mg/m2,day1

DRUG

5-fluorouracil

Participants will receive 5-fluorouracil ,400mg/m2,day1